Wyze Fires Back at JCI - Your Patents Are Invalid, Pay All Of Our Costs

Published Nov 18, 2019 12:02 PM

Goliath JCI targeted startup Wyze this summer alleging the fast-growing consumer startup was violating a slew of JCI's patents.

Now, Wyze has fired back at JCI, not only refusing to pay up but counter alleging that JCI's patents are invalid and that JCI should pay Wyze.

****** **** ****, ** ******* ****'* answer ** ***'* *********, *** ****-****** law **** **** **** ******** *** the ***** ** **** *****.

Wyze ******

** ******** *, ****,**** ******* *********** *** (*** ***** *********** ********'*) complaint:

*** ***** ******** ****** ****** ********** and ****** ** *** ** ******** that ***'* ******* *** *******:

****** ********** ** *** **** ****** way ** ***** ****. *** *******, this ** ******* **** ********** ***** ***** ******** ****** *******. And, ***** **** ** ******* *** approved *** **** ***** *********** **** a **** ******** ****** ** ******* is **** ****** **** ********, **** is * **** **** *** ***. Invalidating *******, ******, ** *********, *** most ****** ********* * **** ****** than ** ******* **** ***** ** costs.

******, **** *** **** **** *** patent ***********, **** **** *** ** pay *** ***** ***** ******* **** case ** ** '***********':

Hired ****-*** *********

********, **** ***** ****-*** ********** ********* to ** ** ******* ***:

**** ************* ****** ** ******* ** * ********** ** ************ Property *** **** ** ******* *** and****** **** ** ************* ************ ******** ********** *** **** to ******** ***. ******,******** * *** ******* ******-***** *** firm.

Outlook - *********** *** ***

**** **** *******, *** ******** *** on ****, ***** ***'* **** *********. The ******** ******* **** **** ** will **** *** **** *** **** Wyze *** ***** *** **** ******* and *** ********* ****** ** ***'* complaint. ** **** ******** **** ** are **** ******* ** ***** *** money ** (*** **) ********** ***'* patents?

Vote / ****

Comments (7)
JE
Jeremy Ellis
Nov 18, 2019

* ***’* ***** ** **** ****** information ** **** **** ***. ***’* wait ***** ***** *** ********* *******.

(2)
JH
John Honovich
Nov 19, 2019
IPVM
Avatar
Ian Ginsberg
Nov 19, 2019

* ******* **** *** ***** ** IPVM, **** *** *** ** ****. I ***'* ***** ***** **** ** any "*******" ** **** *********. ** matter *** **** **** *** *** either *******, *** ********* *** ******* of ***** ******** *** ******** **** ultimately ** *** ****** ** ****, as **** **** *** *** ***** of **** ******** ** **** ******** and ******** **** **** ** *** result ** *** **** ** *** court *******.

UI
Undisclosed Integrator #1
Nov 19, 2019

**** ****** **** ** ******** ** an ******* *******. **** **** ** mind **** ******, ******* ** *** lose *** ****** *** **** *** revealed * ***** ******. ** ***** $50,000/yr *** ******** ** ****** * patent **** ***** *** ***** ** us. ** ******** ********** *** ***** to **** *************, ******* *********** *******, and ** ********* ****** ******** *** following **** *******.

(1)
UM
Undisclosed Manufacturer #2
Nov 22, 2019

** *** **** *** ****** *** have *** ******** * ***** ******.

*****'* *** ****** ********* ****** ******* reveal **** ***** ******?

U
Undisclosed #3
Nov 22, 2019

***** **** ****** *** ****'* **** based ** *** ******* *** *** amount ** *********** *****.

"********, **** ***** ****-*** ********** ********* to ** ** ******* ***"

** ****** ** ******* ***** $*** capital ** ****. **** *** ****** choice ***** *** **** ****.

*** **** ******** ** *** '**** louder' ******** ********* **** ** ******* dogs *** **** **** **** ****** at ** * ****** ***... ******** to **** *** *** *** ***** twice ***** ***** ***** ****.

*'* ******* **** *** *** ***'* lawyers ********* **** *** **** ** is.... *** **** ****** **** *** little *** *****'* **** *** ******** to *** * **** ** *** fight.

(1)
JH
John Honovich
Dec 15, 2019
IPVM

******:* ********** ***** *** **** ***** by *** ************ * ********* ***** **** *** October ****:

** *** **** ****, **** ** being ******** ************** ******* **********.

******* **** ******** ** ** * trial ** ** ****** ******* ** be **** ** ***** ** ****** of **** ** ********* *** ******** in *** ********.